Isotope technology firm Eckert & Ziegler said it has signed a contract to manufacture a new pancreatic cancer drug in partnership with a U.S. biotechnology firm.
The new drug combines the benefits of immunotherapy with those of radiotherapy. Antibodies transport a radiation source directly to cancer cells, enabling precise radiation targeting to fight the tumor, Eckert & Ziegler said.
The company's Radiopharma division was chosen as the exclusive manufacturer for the phase III trial of the new treatment in Europe. The agent will be manufactured in Eckert & Ziegler's production location in Braunschweig, Germany, where a radiation specialist will couple the antibodies with the radioisotope yttrium-90 to produce the final active agent, the company said.
Pancreatic cancer is among the most aggressive and difficult-to-treat forms of cancer.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
